McKesson Corporation (MCK)
| Market Cap | 75.62B |
| Revenue (ttm) | 344.58B |
| Net Income (ttm) | 2.83B |
| Shares Out | 125.33M |
| EPS (ttm) | 21.82 |
| PE Ratio | 27.65 |
| Forward PE | 16.54 |
| Dividend | $2.84 (0.47%) |
| Ex-Dividend Date | Mar 3, 2025 |
| Volume | 605,959 |
| Open | 598.51 |
| Previous Close | 595.69 |
| Day's Range | 583.55 - 604.51 |
| 52-Week Range | 464.42 - 637.51 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 637.38 (+5.63%) |
| Earnings Date | Feb 5, 2025 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty ... [Read more]
Financial Performance
In 2023, McKesson's revenue was $308.95 billion, an increase of 11.65% compared to the previous year's $276.71 billion. Earnings were $3.00 billion, a decrease of -15.67%.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MCK stock is "Strong Buy." The 12-month stock price forecast is $637.38, which is an increase of 5.63% from the latest price.
News
McKesson Corporation (MCK) Q3 2025 Earnings Call Transcript
McKesson Corporation. (NYSE:MCK) Q3 2025 Earnings Conference Call February 5, 2025 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Br...
McKesson misses third-quarter revenue estimates
Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its U.S. pharmaceutical segment, which includes branded and specialty drugs.
McKesson Corporation Reports Fiscal 2025 Third Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
McKesson Advances Specialty Leadership; Signs Agreement to Acquire Controlling Interest in PRISM Vision Holdings, LLC
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC (PRISM Vision), a...
McKesson Corporation Declares Quarterly Dividend
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on A...
McKesson's Practice Insights Selected as a 2025 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services
IRVING, Texas--(BUSINESS WIRE)--For the ninth year, CMS has named McKesson a Qualified Clinical Data Registry approved to participate in the Merit-based Incentive Payment System.
McKesson Amplify Empowers State Pharmacy Associations Nationwide with Advocacy Funding
IRVING, Texas--(BUSINESS WIRE)--McKesson Amplify is intended to help protect critical pharmacy services and elevate the profession by strengthening the voice of the industry.
McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and ...
McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a...
12 High-Yield Dividend Aristocrats To Weather The Coming 2025 Storm In Style
The S&P is up almost 28% in 2024, and many investors worry about a melt-up followed by a sharp correction like in 2022 or 2018. A 2025 market correction is likely, but low-volatility, high-yield Divid...
McKesson Corporation (MCK) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
McKesson Corporation (NYSE:MCK) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 8:20 AM ET Company Participants Britt Vitalone - Executive Vice President and Chief Financial Off...
Jim Cramer looks back at the S&P 500s top performing stocks in November
'Mad Money' host Jim Cramer looks at November's top performing S&P 500 stocks and which could continue to perform into the new year.
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
I reiterate a 'Strong Buy' on McKesson, driven by growth from GLP-1 medications and a robust oncology network business, with a fair value of $696 per share. McKesson's acquisition of a 70% interest in...
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson Corporation (MCK) Q2 2025 Earnings Call Transcript
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S. pharmaceuticals segment on robust demand for specialty and branded drugs.
McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at inve...
McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Healthcare is a great defensive sector that has lower amounts of cyclicality than others that depend on the booming economy. With the stock currently down -21.44% off of its all-time high, the stock i...
InspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex Challenges
IRVING, Texas--(BUSINESS WIRE)--InspiroGene™ by McKesson today announced the publication of its inaugural 2024 Cell and Gene Therapy Report: Advancing the Future of Medicine.
McKesson Launches InspiroGene, a Dedicated Business to Guide and Support the Commercialization of Cell and Gene Therapies
IRVING, Texas--(BUSINESS WIRE)--McKesson launches InspiroGene by McKesson, a dedicated business focused solely on supporting the commercialization of cell and gene therapies.
Stock Of The Day: Has McKesson Found Its Bottom And Will It Bounce Back?
The best traders traders focus on key price levels and stock momentum, understanding that oversold stocks at support often experience a rally.
McKesson Corporation Announces Second Quarter Fiscal 2025 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host ...
McKesson - Meet The New Dividend Stock On My Watchlist
McKesson's recent sell-off offers a compelling opportunity, driven by its strong position in healthcare distribution and growing focus on AI and technology for sustainable growth. The company boasts s...
McKesson, News Corporation And 2 Other Stocks Executives Are Selling
The Nasdaq 100 closed lower by over 500 points during Friday's session. Investors, meanwhile, focused on some notable insider trades.